Immutep Shares positive data from phase 2b AIPAC trial
- Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
- The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
- IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
- The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
- The company is trading 7.58 per cent higher at 35.5 cents
